Medication info
Simbarol Tablets (Simvastatin)

Simbarol Tablets (Simvastatin)

Prescription medicationTabletOral
Ingredient · strength
Simvastatin›20mg / 1 tablet
Manufacturer / importer
Ildong Pharmaceutical Co., Ltd.
Appearance
Brownish yellow oval film-coated tablet
Packaging
30 tablets/bottle - 30 tablets/bottle
Approval status
Active

MFDS item code 200300283 · Notified 2003.03.27 · Insurance code 642900890

Summary

Main use
Improvement of hyperlipidemia, improvement of familial hypercholesterolemia in children, and prevention of cardiovascular disease
Who takes it
Adults · Children
Adult dose
Patients must follow a standard cholesterol-lowering diet before and during treatment with this medicine. 1. Reduction of risk of cardiovascular disease Adult patients at high risk of coronary heart disease events because of a history of coronary heart disease, diabetes, peripheral vascular disease, stroke, or other cerebrovascular disease The recommended initial dose is 40 mg of simvastatin once daily. 2. Hyperlipidemia 1) Reduction of risk in patients with hypercholesterolemia and coronary heart disease, and hyperlipidemia The usual recommended starting dose is 20 mg of this medicine once daily in the evening. Patients with mild to moderate hypercholesterolemia may start with 10 mg of this medicine. Administration of 5 ~ 40 mg of this medicine once daily in the evening is recommended. Adjust the dose appropriately according to the initial LDL cholesterol level before treatment, the treatment goal, and the patient's response to the medicine. Measure cholesterol levels 4 weeks after starting treatment and periodically thereafter to adjust the dose. Reduce the dose if cholesterol levels fall below the target level. Because of the increased risk of myopathy, including rhabdomyolysis, use of the 80 mg dose of this medicine, particularly during the first year of treatment, is restricted to patients who have taken 80 mg of this medicine for 12 months or more without evidence of muscle toxicity (see 1. Warnings under Precautions for Use). 2) For recommended doses in patients receiving this medicine concomitantly with fibrates (excluding gemfibrozil and fenofibrate), amiodarone, verapamil, diltiazem, or amlodipine, and in specific patient groups (i.e., patients with homozygous familial hypercholesterolemia, elderly patients, and patients with renal impairment), see below (see 6. Interactions under Precautions for Use). (1) Administration to patients with homozygous familial hypercholesterolemia Controlled clinical trial results indicate that patients with homozygous familial hypercholesterolemia should receive 40 mg of this medicine once daily in the evening. Administer this medicine in combination with other lipid-lowering treatments (e.g., LDL apheresis), or when other lipid-lowering treatments are not available. (2) In elderly patients, the maximum reduction in cholesterol levels may be achieved with a daily dose of 20 mg of this medicine. (3) Administration to patients receiving verapamil, diltiazem, or dronedarone When this medicine is coadministered to patients receiving verapamil, diltiazem, or dronedarone, the dose of this medicine must not exceed 10 mg daily. (4) Administration to patients receiving amiodarone, amlodipine, or ranolazine When this medicine is coadministered to patients receiving amiodarone, amlodipine, or ranolazine, the dose of this medicine must not exceed 20 mg daily. (5) Coadministration with other lipid-lowering agents This medicine is effective when administered alone or in combination with a bile acid sequestrant. When this medicine is coadministered with a fibrate (excluding gemfibrozil (see 2. Patients Who Must Not Receive This Medicine under Precautions for Use) and fenofibrate), the dose of this medicine must not exceed 10 mg daily. (6) Administration to patients with renal impairment Because this medicine is not extensively excreted by the kidneys, no dose adjustment is required in patients with mild to moderate renal impairment. In patients with severe renal impairment, however, start treatment at 5 mg daily and monitor carefully.
Child dose
Pediatric patients with heterozygous familial hypercholesterolemia (10 ~ 17 years): The recommended initial dose is 10 mg of this medicine once daily in the evening. The recommended dose range is 10 ~ 40 mg daily, with a maximum recommended dose of 40 mg daily. Adjust the dose individually according to the recommended treatment goal. Allow an interval of 4 weeks or more between dose adjustments.

Ingredients

Manufacturer
Ildong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of hyperlipidemia, improvement of familial hypercholesterolemia in children, and prevention of cardiovascular disease

  • Coronary heart disease
  • diabetes
  • peripheral vascular disease
  • stroke
  • other cerebrovascular diseases
  • non-fatal myocardial infarction
  • hypercholesterolemia
  • dyslipidemia
  • abnormal beta-lipoproteinemia
  • hypertriglyceridemia
  • heterozygous familial hypercholesterolemia
View approved original text

This medication helps reduce the risk of cardiovascular diseases. It lowers the risk of heart disease mortality, myocardial infarction, and stroke in patients with a history of coronary heart disease, diabetes, peripheral vascular disease, and stroke. It also reduces the risk of coronary and non-coronary vascular interventions. When treating hyperlipidemia, it lowers total cholesterol, LDL cholesterol, and apo-B levels, while increasing HDL cholesterol levels, thereby improving blood lipid levels. It is especially effective in controlling cholesterol levels in patients with familial hypercholesterolemia and in pediatric patients when used alongside dietary measures. This medication is used to treat a variety of cardiovascular diseases and hyperlipidemia.

How to take

Adult dose

Patients must follow a standard cholesterol-lowering diet before and during treatment with this medicine. 1. Reduction of risk of cardiovascular disease Adult patients at high risk of coronary heart disease events because of a history of coronary heart disease, diabetes, peripheral vascular disease, stroke, or other cerebrovascular disease The recommended initial dose is 40 mg of simvastatin once daily. 2. Hyperlipidemia 1) Reduction of risk in patients with hypercholesterolemia and coronary heart disease, and hyperlipidemia The usual recommended starting dose is 20 mg of this medicine once daily in the evening. Patients with mild to moderate hypercholesterolemia may start with 10 mg of this medicine. Administration of 5 ~ 40 mg of this medicine once daily in the evening is recommended. Adjust the dose appropriately according to the initial LDL cholesterol level before treatment, the treatment goal, and the patient's response to the medicine. Measure cholesterol levels 4 weeks after starting treatment and periodically thereafter to adjust the dose. Reduce the dose if cholesterol levels fall below the target level. Because of the increased risk of myopathy, including rhabdomyolysis, use of the 80 mg dose of this medicine, particularly during the first year of treatment, is restricted to patients who have taken 80 mg of this medicine for 12 months or more without evidence of muscle toxicity (see 1. Warnings under Precautions for Use). 2) For recommended doses in patients receiving this medicine concomitantly with fibrates (excluding gemfibrozil and fenofibrate), amiodarone, verapamil, diltiazem, or amlodipine, and in specific patient groups (i.e., patients with homozygous familial hypercholesterolemia, elderly patients, and patients with renal impairment), see below (see 6. Interactions under Precautions for Use). (1) Administration to patients with homozygous familial hypercholesterolemia Controlled clinical trial results indicate that patients with homozygous familial hypercholesterolemia should receive 40 mg of this medicine once daily in the evening. Administer this medicine in combination with other lipid-lowering treatments (e.g., LDL apheresis), or when other lipid-lowering treatments are not available. (2) In elderly patients, the maximum reduction in cholesterol levels may be achieved with a daily dose of 20 mg of this medicine. (3) Administration to patients receiving verapamil, diltiazem, or dronedarone When this medicine is coadministered to patients receiving verapamil, diltiazem, or dronedarone, the dose of this medicine must not exceed 10 mg daily. (4) Administration to patients receiving amiodarone, amlodipine, or ranolazine When this medicine is coadministered to patients receiving amiodarone, amlodipine, or ranolazine, the dose of this medicine must not exceed 20 mg daily. (5) Coadministration with other lipid-lowering agents This medicine is effective when administered alone or in combination with a bile acid sequestrant. When this medicine is coadministered with a fibrate (excluding gemfibrozil (see 2. Patients Who Must Not Receive This Medicine under Precautions for Use) and fenofibrate), the dose of this medicine must not exceed 10 mg daily. (6) Administration to patients with renal impairment Because this medicine is not extensively excreted by the kidneys, no dose adjustment is required in patients with mild to moderate renal impairment. In patients with severe renal impairment, however, start treatment at 5 mg daily and monitor carefully.

Child dose

Pediatric patients with heterozygous familial hypercholesterolemia (10 ~ 17 years): The recommended initial dose is 10 mg of this medicine once daily in the evening. The recommended dose range is 10 ~ 40 mg daily, with a maximum recommended dose of 40 mg daily. Adjust the dose individually according to the recommended treatment goal. Allow an interval of 4 weeks or more between dose adjustments.

Precautions

This medication can cause muscle-related side effects such as myopathy and rhabdomyolysis; therefore, caution is especially needed when taking high doses. If unexplained muscle pain or muscle weakness occurs during the use of this medication, inform your doctor immediately, and stop taking the medication if necessary. Since this medication is primarily metabolized in the liver, patients with poor liver function or those who consume alcohol heavily should regularly monitor their liver health. Women who are pregnant or may become pregnant, and nursing mothers should not take this medication and must stop if pregnancy is confirmed during treatment. This medication can interact with certain drugs, increasing blood concentration levels and potentially raising the risk of muscle damage; thus, patients should consult with their doctor or pharmacist if they are taking other medications. Elderly patients or those with reduced kidney function, and patients with hypothyroidism need careful monitoring while taking this medication. If liver dysfunction is suspected, liver function tests should be performed, and treatment should be stopped immediately if symptoms of hepatitis or jaundice appear. It is advisable to avoid certain foods such as grapefruit juice while taking this medication, and inform other doctors that you are taking this medication when receiving other treatments. This medication is used with restrictions in children and adolescents, especially not administered to children under 10 years. In case of overdose, seek appropriate treatment at the hospital immediately, and store in a place out of reach of children in its original container.

Side effects

  • Myopathy
  • rhabdomyolysis
  • abdominal pain
  • weakness
  • constipation
  • diarrhea
  • dyspepsia
  • bloating
  • nausea
  • headache
Show 88 more
  • upper respiratory infection
  • edema
  • atrial fibrillation
  • gastritis
  • diabetes
  • myalgia
  • insomnia
  • dizziness
  • bronchitis
  • sinusitis
  • eczema
  • urinary tract infection
  • muscle cramps
  • arthralgia
  • dysgeusia
  • extraocular muscle movement disorder
  • facial paralysis
  • tremor
  • sensory disturbance
  • peripheral neuropathy
  • peripheral nerve paralysis
  • psychiatric disorders
  • anxiety
  • sleep disorders
  • nightmares
  • depression
  • cognitive impairment
  • myasthenia gravis
  • oculomotor myasthenia
  • hepatitis
  • liver dysfunction
  • jaundice
  • pancreatitis
  • liver failure
  • cholestatic jaundice
  • fatty liver disease
  • cirrhosis
  • fulminant liver necrosis
  • liver cancer
  • loss of appetite
  • vomiting
  • alopecia
  • pruritus
  • skin changes
  • lichen-planus-like drug rash
  • gynecomastia
  • decreased libido
  • sexual dysfunction
  • cataract progression
  • ophthalmoplegia
  • anemia
  • elevated aminotransferases
  • elevated ALP
  • elevated γ-GTP
  • elevated bilirubin levels
  • thyroid dysfunction
  • elevated serum creatine kinase
  • interstitial lung disease
  • anaphylaxis
  • angioedema
  • lupus-like syndrome
  • polymyositis
  • dermatomyositis
  • vasculitis
  • purpura
  • thrombocytopenia
  • leukopenia
  • hemolytic anemia
  • positive antinuclear antibody
  • increased erythrocyte sedimentation rate
  • eosinophilia
  • arthritis
  • urticaria
  • photosensitivity
  • fever
  • chills
  • flushing
  • fatigue
  • dyspnea
  • toxic epidermal necrolysis
  • sicca syndrome
  • erythema multiforme
  • sensory numbness in the limbs
  • paresthesia
  • cold sensation
  • muscle weakness
  • thrombocytopenia
  • abnormal liver function tests

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a sealed container. It is best to maintain a storage temperature between 1 degree and 30 degrees Celsius to preserve its effectiveness for a longer period.

Appearance and packaging

Appearance

Brownish yellow oval film-coated tablet

Package unit

30 tablets/bottle - 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.